As we analyze the forecasted import values of insulin in dosage forms to the US from 2024 to 2028, there is a noticeable downward trend. The import value starts at $2.0602 billion in 2024 and gradually declines to $1.9658 billion by 2028. Comparing this to the actual figure from 2023, which stood at $2.085 billion, the year-on-year decrease highlights a consistent reduction in import value. The average compound annual growth rate (CAGR) over these five years is slightly negative, indicating a declining market interest or improved local production capabilities.
Future trends to watch for include advancements in local insulin production, potential regulatory changes impacting import volumes, and shifts in domestic demand influenced by healthcare innovations or policy amendments. Monitoring these factors can provide insights into the dynamics driving the US insulin import market.
